Price
Target price
€42.20
€42.20
2.930%
1.2
2.930%
€84.74
22:26 / Tradegate
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
There is an upward development for Ultragenyx Pharmaceutical Inc. compared to yesterday, with an increase of €1.20 (2.930%).
With 15 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 84 € there is a hugely positive potential of 99.05% for Ultragenyx Pharmaceutical Inc. compared to the current price of 42.2 €.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 2.930% | -1.485% | -6.132% | 5.851% | -8.716% | -56.264% | -34.496% |
| Iovance Biotherapeutics Inc. | 4.420% | -4.917% | -23.544% | 99.307% | 36.206% | -58.970% | - |
| Novocure Ltd | 2.030% | -5.219% | -6.738% | -80.123% | -20.490% | -93.150% | - |
| Fibrogen Inc. | 2.770% | -13.228% | -55.583% | -94.269% | 23.953% | -93.931% | - |
Comments
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat